Effects of Darbepoetin Alfa Administered Every Two Weeks on Hemoglobin and Quality of Life of Patients Receiving Chemotherapy
Purpose/Objectives: To review the effects on hemoglobin and quality of life of an every-two-week (Q2W) regimen of the erythropoietic agent darbepoetin alfa for treating patients with chemotherapy-induced anemia.
Members Only
Access to this article is restricted. Please log in to view the full article.